Clinical Trial Update: Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating camrelizumab in combination with rivoceranib and hepatic arterial infusion chemotherapy as conversion therapy for potentially resec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Rivoceranib (rivoceranib)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Potentially Resectable Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING